EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeting on the PI3K/mTOR: a potential treatment strategy for clear cell ovarian carcinoma

Kewei Zheng, Guanqin Jin, Rui Cao, Yi Gao, Jing Xu, Ranran Chai, Yu Kang

Cancer Chemotherapy and Pharmacology · 2025

DOI: 10.1007/s00280-024-04748-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2025. Verfasst von Kewei Zheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, 200011, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, TOR Serine-Threonine Kinases, Adenocarcinoma, Clear Cell, Cisplatin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsTOR Serine-Threonine KinasesAdenocarcinoma, Clear CellCisplatinApoptosisPhosphatidylinositol 3-KinasesCell ProliferationFemaleHumansAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysMice, NudeSignal TransductionPhosphoinositide-3 Kinase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsProto-Oncogene Proteins c-aktMTOR InhibitorsMice, Inbred BALB CAntineoplastic Agents

Stichwörter der Autor:innen

ApoptosisAutophagyCombination therapyOvarian clear cell carcinomaProliferationTargeted therapy

Substanzen

TOR Serine-Threonine KinasesMTOR protein, humanCisplatinPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProto-Oncogene Proteins c-aktMTOR InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, 200011, China.
  • Department of Gynecology, Dalian Obstetrics and Gynecology Hospital, Dalian, 116033, China.
  • Department of Obstetrics and Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, 200011, China. yukang@fudan.edu.cn.

Förderung

  • National Key Research and Development Program of China

Zitieren

APA

Zheng, K., Jin, G., Cao, R., Gao, Y., Xu, J., Chai, R., & Kang, Y. (2025). Targeting on the PI3K/mTOR: a potential treatment strategy for clear cell ovarian carcinoma. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-024-04748-3

Vancouver

Zheng K, Jin G, Cao R, Gao Y, Xu J, Chai R, et al. Targeting on the PI3K/mTOR: a potential treatment strategy for clear cell ovarian carcinoma. Cancer Chemotherapy and Pharmacology. 2025. doi:10.1007/s00280-024-04748-3

BibTeX
@article{Zheng2025,
  author = {Zheng, Kewei and Jin, Guanqin and Cao, Rui and Gao, Yi and Xu, Jing and Chai, Ranran and Kang, Yu},
  title = {Targeting on the PI3K/mTOR: a potential treatment strategy for clear cell ovarian carcinoma},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2025},
  doi = {10.1007/s00280-024-04748-3}
}
Kostenlos starten →